Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AURINIA PHARMACEUTICALS INC.

(AUPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aurinia Pharmaceuticals Shares Rally on Report of Bristol Myers Interest

10/25/2021 | 07:10am EST

By Colin Kellaher

Shares of Aurinia Pharmaceuticals Inc. rose more than 10% in premarket trading Monday, adding on to Friday's gains, after Bloomberg reported that Bristol Myers Squibb Co. has expressed interest in acquiring the smaller biopharmaceutical company.

Aurinia shares, which surged nearly 27% on Friday to close at a 52-week high of $28, were recently up 10.7% to $31 in premarket trading.

Bristol Myers recently approached the Victoria, British Columbia, company about an acquisition, Bloomberg reported Friday, citing people familiar with the matter.

The sources said New York-based Bristol Myers hasn't made any final decision and could opt against any potential deal.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-25-21 0910ET

Stocks mentioned in the article
ChangeLast1st jan.
AURINIA PHARMACEUTICALS INC. 13.27% 20.14 Delayed Quote.45.63%
BRISTOL-MYERS SQUIBB COMPANY 0.84% 55.41 Delayed Quote.-10.67%
CORN FUTURES (C) - CBR (FLOOR)/C1 0.87% 577 End-of-day quote.18.18%
All news about AURINIA PHARMACEUTICALS INC.
12/02CORRECTION : Aurinia Pharmaceuticals Stock Rebounds From Wednesday's Decline
MT
12/02Aurinia Pharmaceuticals Stock Rebounds From Tuesday's Decline
MT
11/22Health Care Stocks Finishing Mixed This Afternoon
MT
11/22Top Midday Decliners
MT
11/22Health Care Stocks Drifting Near Unchanged Mark Monday
MT
11/22Aurinia Pharmaceuticals Shares Sink After Filing Prospectus to Sell $250 Million Securi..
MT
11/22Wall Street Sees Upbeat Open as Potential China Easing Lifts Sentiment
MT
11/22Top Premarket Decliners
MT
11/22Aurinia Pharmaceuticals Plans $250 Million Securities Offering -- Shares Slump in Pre-M..
MT
11/10Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
BU
More news
Analyst Recommendations on AURINIA PHARMACEUTICALS INC.
More recommendations
Financials (USD)
Sales 2021 45,7 M - -
Net income 2021 -181 M - -
Net cash 2021 254 M - -
P/E ratio 2021 -14,3x
Yield 2021 -
Capitalization 2 612 M 2 612 M -
EV / Sales 2021 51,6x
EV / Sales 2022 11,6x
Nbr of Employees 294
Free-Float 92,3%
Chart AURINIA PHARMACEUTICALS INC.
Duration : Period :
Aurinia Pharmaceuticals Inc. Technical Analysis Chart | AUPH | CA05156V1022 | MarketScreener
Technical analysis trends AURINIA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 20,14 $
Average target price 32,00 $
Spread / Average Target 58,9%
EPS Revisions
Managers and Directors
Peter S. Greenleaf President, Chief Executive Officer & Director
Joseph M. Miller Chief Financial Officer
George M. Milne Chairman
Robert B. Huizinga Executive Vice President-Research
Neil Solomons Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AURINIA PHARMACEUTICALS INC.45.63%2 612
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.13%65 499
VERTEX PHARMACEUTICALS-13.49%51 982